Key Takeaways:
Sino Biopharm (01177.HK) announced that early data from a 112-patient study of its innovative cancer drug, MK-2010/LM-299, demonstrated preliminary anti-tumor activity and a manageable safety profile, supporting its advancement in clinical trials.
The data was presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting by the company's wholly-owned subsidiary, Livzon Mabpharm, which developed the drug.
The study evaluated the PD-1/VEGF bispecific antibody across a range of doses in 112 total patients. While specific efficacy and safety metrics were not fully disclosed, the company confirmed the results were strong enough to warrant continued development as either a monotherapy or part of a combination therapy.
The positive, albeit early, results could bolster investor confidence in Sino Biopharm’s oncology pipeline. Success in developing novel cancer therapies like this bispecific antibody is crucial for competing in a crowded market and could unlock significant future revenue streams pending further trial success and regulatory approval.
The advancement of MK-2010/LM-299 strengthens Sino Biopharm's position in the innovative oncology space. Investors will be closely watching for the initiation of Phase 2 trials and more detailed data on efficacy and safety in specific cancer types.
This article is for informational purposes only and does not constitute investment advice.
